Response of Bortezomib Chemotherapy in Hepatic Amyloidosis

Overview

Journal J Investig Med High Impact Case Rep

Specialty General Medicine

Date 2018 Mar 20

PMID 29552568

Authors

Syed M Hasan

Nida N Ahmed

Zunirah Ahmed

Allan Seibert

Affiliations

Soon will be listed here.

Abstract

Amyloidosis is a rare disorder with a wide spectrum of presentations and anomalies. It is subdivided into 2 broad categories based on protein deposition; primary and secondary amyloidosis. It can present as a single-organ involvement or as a diffuse infiltrative multi-organ process. Isolated hepatic amyloidosis presentation is a rare phenomenon that develops due to insoluble amyloid deposition in liver. Its clinical presentation is usually vague and ranges from mild hepatomegaly with elevated liver enzymes to acute liver failure and hepatic rupture. Currently, there are scarce data available regarding treatment options for biopsy-proven hepatic amyloidosis. In this review article, we present an interesting case of hepatic amyloidosis and its poor outcome to new molecular targeted chemotherapy. Furthermore, we aim to review current and future diagnostic tools for early detection and advancements in targeted chemotherapeutics options available for hepatic amyloidosis.

References

Nakano R, Ohira M, Ide K, Ishiyama K, Kobayashi T, Tahara H . Treatment of hepatic amyloid light-chain amyloidosis with bortezomib and dexamethasone in a liver transplant patient. Hepatol Res. 2014; 45(10):E150-5. DOI: 10.1111/hepr.12462. View

Mainenti P, dAgostino L, Soscia E, Romano M, Salvatore M . Hepatic and splenic amyloidosis: dual-phase spiral CT findings. Abdom Imaging. 2003; 28(5):688-90. DOI: 10.1007/s00261-003-0016-z. View

Takayasu V, Laborda L, Bernardelli R, Pinesi H, Silva M, Chiavelli V . Amyloidosis: an unusual cause of portal hypertension. Autops Case Rep. 2016; 6(2):9-18. PMC: 4982779. DOI: 10.4322/acr.2016.035. View

Park M, Mueller P, Kyle R, Larson D, Plevak M, Gertz M . Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine (Baltimore). 2003; 82(5):291-8. DOI: 10.1097/01.md.0000091183.93122.c7. View

Gertz M, Kyle R . Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med. 1988; 85(1):73-80. DOI: 10.1016/0002-9343(88)90505-0. View

Pepys M . Amyloidosis. Annu Rev Med. 2006; 57:223-41. DOI: 10.1146/annurev.med.57.121304.131243. View

Gertz M, Kyle R . Primary systemic amyloidosis--a diagnostic primer. Mayo Clin Proc. 1989; 64(12):1505-19. DOI: 10.1016/s0025-6196(12)65706-1. View

Peters R, Koukoulis G, Gimson A, Portmann B, Westaby D, Williams R . Primary amyloidosis and severe intrahepatic cholestatic jaundice. Gut. 1994; 35(9):1322-5. PMC: 1375717. DOI: 10.1136/gut.35.9.1322. View

Kyle R, Greipp P . Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clin Proc. 1983; 58(10):665-83. View

10.

Monzawa S, Tsukamoto T, Omata K, Hosoda K, Araki T, Sugimura K . A case with primary amyloidosis of the liver and spleen: radiologic findings. Eur J Radiol. 2002; 41(3):237-41. DOI: 10.1016/s0720-048x(01)00407-7. View

11.

Kim S, Kang E, Park J, Jo J, Kim S, Cho J . Gastrointestinal amyloidosis presenting with multiple episodes of gastrointestinal bleeding. Cardiovasc Intervent Radiol. 2008; 32(3):577-80. DOI: 10.1007/s00270-008-9429-y. View

12.

Sitia R, Palladini G, Merlini G . Bortezomib in the treatment of AL amyloidosis: targeted therapy?. Haematologica. 2007; 92(10):1302-7. DOI: 10.3324/haematol.12136. View

13.

Lachmann H, Goodman H, Gilbertson J, Gallimore J, Sabin C, Gillmore J . Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356(23):2361-71. DOI: 10.1056/NEJMoa070265. View

14.

Girnius S, Seldin D, Skinner M, Finn K, Quillen K, Doros G . Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease. Haematologica. 2009; 94(7):1029-32. PMC: 2704317. DOI: 10.3324/haematol.2008.001925. View

15.

Gertz M, Lacy M, Dispenzieri A . Amyloidosis. Hematol Oncol Clin North Am. 2000; 13(6):1211-33, ix. DOI: 10.1016/s0889-8588(05)70122-2. View

16.

Sonthalia N, Jain S, Pawar S, Zanwar V, Surude R, Rathi P . Primary hepatic amyloidosis: A case report and review of literature. World J Hepatol. 2016; 8(6):340-4. PMC: 4766262. DOI: 10.4254/wjh.v8.i6.340. View

17.

Mikhael J, Schuster S, Jimenez-Zepeda V, Bello N, Spong J, Reeder C . Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012; 119(19):4391-4. PMC: 3557400. DOI: 10.1182/blood-2011-11-390930. View

18.

Venner C, Lane T, Foard D, Rannigan L, Gibbs S, Pinney J . Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012; 119(19):4387-90. DOI: 10.1182/blood-2011-10-388462. View

19.

Yim B, Kertowidjojo E, Zhang Y, Patel P . Poor Outcomes in Hepatic Amyloidosis: A Report of 2 Cases. Case Rep Oncol Med. 2016; 2016:7625940. PMC: 5059556. DOI: 10.1155/2016/7625940. View

20.

Shiva Kumar K, Lefkowitch J, Russo M, Hesdorffer C, Kinkhabwala M, Kapur S . Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis. Gastroenterology. 2002; 122(7):2026-31. DOI: 10.1053/gast.2002.33648. View